Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Evercore HealthCONx Conference Transcript

Dec 04, 2019 / 02:30PM GMT
Release Date Price: R$16.11
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

(technical difficulty)

I guess priorities heading into year-end as well as 2020, and we'll take it from there.

Daniel M. Skovronsky
Eli Lilly and Company - Senior VP & Chief Scientific Officer

Yes. Sure. Well, it's an exciting time at Lilly. Of course, there's a lot of data readouts, that's what gets me the most excited, coming soon. Of course, this is a big week. We have a disclosure coming up at ASH. We have an Alzheimer's portfolio that's moving forward, so we're closely watching what's happening at CTAD as well. Yet by the end of this year, we have beginning of data readouts on Jardiance for heart failure, more of that coming next year. And then next year, we also get to see tirzepatide data. That's our GIP/GLP molecule in Phase III. We'll see the first Phase III readouts next year as well as our first Phase III for an IL-23 in IBD. That's mirikizumab in ulcerative colitis. So a lot to look forward to and a lot going on at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot